Genetic Insights from the ADSP into Drug Discovery In Alzheimer’s Disease

A major goal of the NAPA plan initiated in 2013 is the development of novel drugs for the treatment and prevention of Alzheimer’s disease (AD). It is widely recognized that drug targets with genetic support are more likely to successfully make it through the drug development pipeline than those without genetic support. The target may be a genetic risk factor for AD or within a genetically regulated network implicated by an AD genetic risk factor. Thus, one of the primary goals of the Alzheimer’s disease sequencing project (ADSP) is to identify and validate putative novel drug targets and to work with the community to advance testing of these candidates.